Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 12OTHER 5NIH 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Multiple Myeloma 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × NIH × pevonedistat × Clear all
NCT03772925 2026-03-03

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Terminated
18 enrolled 19 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03770260 2025-06-19

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1 Completed
8 enrolled 11 charts
Plasma cell

Multiple Myeloma

NCT03813147 2025-04-13

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 16 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡